2023
ISPD Catheter-related Infection Recommendations: 2023 Update
Chow K, Li P, Cho Y, Abu-Alfa A, Bavanandan S, Brown E, Cullis B, Edwards D, Ethier I, Hurst H, Ito Y, de Moraes T, Morelle J, Runnegar N, Saxena A, So S, Tian N, Johnson D. ISPD Catheter-related Infection Recommendations: 2023 Update. Advances In Peritoneal Dialysis 2023, 43: 201-219. PMID: 37232412, DOI: 10.1177/08968608231172740.Peer-Reviewed Original ResearchConceptsDialysis catheter-related infectionsExit-site infection rateAntibiotic treatment durationCatheter exit siteExit-site infectionDuration of therapyCatheter-related infectionsImportant risk factorExit siteCatheter lossCatheter removalTunnel infectionSite infectionCuff removalAntibiotic creamCatheter interventionRisk factorsTreatment durationClinical monitoringInfection rateInfectionNew targetsNew recommendationsDurationPeritonitis
2019
Heart failure in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference
House A, Wanner C, Sarnak M, Piña I, McIntyre C, Komenda P, Kasiske B, Deswal A, deFilippi C, Cleland J, Anker S, Herzog C, Cheung M, Wheeler D, Winkelmayer W, McCullough P, Participants C, Abu-Alfa A, Amann K, Aonuma K, Appel L, Baigent C, Bakris G, Banerjee D, Boletis J, Bozkurt B, Butler J, Chan C, Costanzo M, Dubin R, Filippatos G, Gikonyo B, Gikonyo D, Hajjar R, Iseki K, Ishii H, Knoll G, Lenihan C, Lentine K, Lerma E, Macedo E, Mark P, Noiri E, Palazzuoli A, Pecoits-Filho R, Pitt B, Rigatto C, Rossignol P, Setoguchi S, Sood M, Störk S, Suri R, Szummer K, Tang S, Tangri N, Thompson A, Vijayaraghavan K, Walsh M, Wang A, Weir M. Heart failure in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney International 2019, 95: 1304-1317. PMID: 31053387, DOI: 10.1016/j.kint.2019.02.022.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsChronic kidney diseaseDialysis-dependent chronic kidney diseaseNondialysis chronic kidney diseaseHeart failureKidney diseaseEjection fractionGlobal outcomeKidney transplant patientsReduced ejection fractionControversies ConferenceTransplant patientsBreakout group discussionsDiseaseOutcomesFailureHFpEFPatientsGroup discussionsPrevalenceIncidenceDiagnosisPrevention
2018
Improving the prognosis of patients with severely decreased glomerular filtration rate (CKD G4+): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference
Eckardt K, Bansal N, Coresh J, Evans M, Grams M, Herzog C, James M, Heerspink H, Pollock C, Stevens P, Tamura M, Tonelli M, Wheeler D, Winkelmayer W, Cheung M, Hemmelgarn B, Participants C, Abu-Alfa A, Anand S, Arici M, Ballew S, Block G, Burgos-Calderon R, Charytan D, Das-Gupta Z, Dwyer J, Fliser D, Froissart M, Gill J, Griffith K, Harris D, Huffman K, Inker L, Jager K, Jun M, Kalantar-Zadeh K, Kasiske B, Kovesdy C, Krane V, Lamb E, Lerma E, Levey A, Levin A, Mauro J, Nash D, Navaneethan S, O’Donoghue D, Obrador G, Pecoits-Filho R, Robinson B, Schäffner E, Segev D, Stengel B, Stenvinkel P, Tangri N, Tentori F, Tsukamoto Y, Turakhia M, Vazquez M, Wang A, Williams A. Improving the prognosis of patients with severely decreased glomerular filtration rate (CKD G4+): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney International 2018, 93: 1281-1292. PMID: 29656903, PMCID: PMC5998808, DOI: 10.1016/j.kint.2018.02.006.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsGlomerular filtration rateKidney replacement therapyCKD G4Kidney failureFiltration rateRisk factorsGlobal outcomeTraditional CVD risk factorsCKD Prognosis ConsortiumCVD risk factorsCardiovascular disease eventsPrognosis of patientsOptimal therapeutic strategyControversies ConferenceCohort studyCVD outcomesHeart failureVariable prognosisClinical outcomesTherapeutic challengeKidney diseasePrognostic valueReplacement therapyInternational expert groupPatient preferencesKidney disease in the setting of HIV infection: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference
Swanepoel C, Atta M, D’Agati V, Estrella M, Fogo A, Naicker S, Post F, Wearne N, Winkler C, Cheung M, Wheeler D, Winkelmayer W, Wyatt C, Participants C, Abu-Alfa A, Adu D, Agodoa L, Alpers C, Arogundade F, Ashuntantang G, Bagnis C, Bhimma R, Brocheriou I, Cohen A, Cohen K, Cook H, de Seigneux S, Fabian J, Finkelstein F, Haas M, Hamzah L, Hendry B, Imonje V, Jennette J, Kimmel P, Klotman M, Klotman P, Larsen C, McCulloch M, Mosiane P, Nast C, Okpechi I, Ray P, Rosenberg A, Ross M, Ryom L, Truong L, Ulasi I, Vogt L, Zeier M. Kidney disease in the setting of HIV infection: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney International 2018, 93: 545-559. PMID: 29398134, PMCID: PMC5983378, DOI: 10.1016/j.kint.2017.11.007.Peer-Reviewed Original ResearchConceptsHIV-positive individualsKidney diseaseAntiretroviral therapyHIV infectionImmune complex kidney diseaseKidney disease preventionHIV-associated nephropathyFocal segmental glomerulosclerosisUnique HIVKidney injuryOpportunistic infectionsHIV treatmentClinical guidelinesRenal pathologySegmental glomerulosclerosisGeneral populationRole of geneticsGlobal outcomeDisease preventionNatural historyInfectious diseasesDiseaseInfectionGenetic factorsPrevention
2011
Nephrogenic Systemic Fibrosis and Gadolinium-Based Contrast Agents
Abu-Alfa AK. Nephrogenic Systemic Fibrosis and Gadolinium-Based Contrast Agents. Advances In Kidney Disease And Health 2011, 18: 188-198. PMID: 21531325, DOI: 10.1053/j.ackd.2011.03.001.Peer-Reviewed Original ResearchConceptsAcute kidney injuryNephrogenic systemic fibrosisGadolinium-based contrast agentsCKD stage 4Immediate hemodialysisSystemic fibrosisAdministration of GBCAsCare of patientsStage 4Needs of patientsMajority of casesKidney injuryDialysis initiationPeritoneal dialysisSignificant morbidityKidney diseaseCurrent recommendationsHigh riskContrast agentsLower riskRisk differencePatientsDrug AdministrationHemodialysisIndividualized assessment
2010
Tumor Lysis Syndrome and Acute Kidney Injury: Evaluation, Prevention, and Management
Abu-Alfa AK, Younes A. Tumor Lysis Syndrome and Acute Kidney Injury: Evaluation, Prevention, and Management. American Journal Of Kidney Diseases 2010, 55: s1-s13. PMID: 20420966, DOI: 10.1053/j.ajkd.2009.10.056.BooksConceptsTumor lysis syndromeAcute kidney injuryKidney injuryLysis syndromeKidney functionRisk factorsClinical tumor lysis syndromePatient-specific risk factorsPatient's kidney functionMassive tumor cell deathSerious clinical complicationsIdentification of tumorsTumor cell deathCardiac arrestClinical complicationsEarly recognitionClinical abnormalitiesEfficacious interventionsSecondary hypocalcemiaInjurySyndromeCell deathHypocalcemiaHyperkalemiaHyperphosphatemia
2008
Nephrogenic systemic fibrosis—Implications for nephrologists
Saab G, Abu-Alfa A. Nephrogenic systemic fibrosis—Implications for nephrologists. European Journal Of Radiology 2008, 66: 208-212. PMID: 18342470, DOI: 10.1016/j.ejrad.2008.01.028.BooksMeSH KeywordsContrast MediaFibrosisGadoliniumHumansKidney DiseasesMagnetic Resonance ImagingRisk FactorsSkin DiseasesConceptsRisk of NSFChronic kidney diseaseNephrogenic systemic fibrosisContrast-induced nephropathyAdvanced chronic kidney diseaseDevelopment of NSFAdministration of gadoliniumErythropoietin therapyNephrologist's perspectiveKidney diseaseMetabolic acidosisRisk factorsMineral metabolismSystemic fibrosisNephrologist's roleHigh dosesGd-CARecent evidenceRiskContrast agentsNephropathyNephrologistsPatientsFibrosisAcidosisThe Impact of NSF on the Care of Patients With Kidney Disease
Abu-Alfa A. The Impact of NSF on the Care of Patients With Kidney Disease. Journal Of The American College Of Radiology 2008, 5: 45-52. PMID: 18180009, DOI: 10.1016/j.jacr.2007.08.018.Peer-Reviewed Original ResearchConceptsEnd-stage renal diseaseChronic kidney diseaseNephrogenic systemic fibrosisGlomerular filtration rateCare of patientsGadolinium-based magnetic resonance contrast agentsRenal diseasePeritoneal dialysisKidney diseaseFiltration rateSystemic fibrosisStage 4 chronic kidney diseaseCases of NSFNormal glomerular filtration rateAcute kidney injurySessions of hemodialysisMajority of casesCKD patientsKidney injuryMagnetic resonance contrast agentsSignificant morbidityPD patientsVascular accessProlonged eliminationOdds ratio
2007
Are Patients with Moderate Renal Failure at Risk for Developing Nephrogenic Systemic Fibrosis?
Saab G, Abu-Alfa A. Are Patients with Moderate Renal Failure at Risk for Developing Nephrogenic Systemic Fibrosis? Radiology 2007, 244: 930-932. PMID: 17709844, DOI: 10.1148/radiol.2443070351.Peer-Reviewed Original ResearchWill dialysis prevent the development of nephrogenic systemic fibrosis after gadolinium-based contrast administration?
Saab G, Abu-Alfa A. Will dialysis prevent the development of nephrogenic systemic fibrosis after gadolinium-based contrast administration? American Journal Of Roentgenology 2007, 189: w169. PMID: 17715089, DOI: 10.2214/ajr.07.2252.Peer-Reviewed Original ResearchGadolinium-based MR Contrast Agents and Nephrogenic Systemic Fibrosis1
Kuo PH, Kanal E, Abu-Alfa AK, Cowper SE. Gadolinium-based MR Contrast Agents and Nephrogenic Systemic Fibrosis1. Radiology 2007, 242: 647-9. PMID: 17213364, DOI: 10.1148/radiol.2423061640.Commentaries, Editorials and Letters